Dr Peter Chapman, Our people, University of Otago, Christchurch

BSc, M.D(Otago) FRACP, PGDipMSM(Otago)

Peter is a Rheumatologist and Clinical Director of Department of Rheumatology, Immunology and Allergy, Canterbury District Health Board.

He has a broad range of interests in Rheumatology and is involved in undergraduate and postgraduate education.

Publications

Stamp, L., Horne, A., Mihov, B., Drake, J., Haslett, J., Chapman, P. T., Frampton, C., & Dalbeth, N. (2023). Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial. Annals of the Rheumatic Diseases, 82, 1626-1634. doi: 10.1136/ard-2023-224731

Lyne, S. A., Ruediger, C., Lester, S., Chapman, P. T., Shanahan, E. M., Hill, C. L., & Stamp, L. (2022). Giant cell arteritis: A population-based retrospective cohort study exploring incidence and clinical presentation in Canterbury, Aotearoa New Zealand. Frontiers in Medicine, 9, 1057917. doi: 10.3389/fmed.2022.1057917

Li, B., Falvey, J., Pike, L., Sies, C., Chapman, P., & Florkowski, C. (2022). A case of macroenzyme aspartate aminotransferase (macro-AST) in a patient with seronegative rheumatoid arthritis. New Zealand Medical Journal, 135(1558), 106-109. Retrieved from https://journal.nzma.org.nz

Monti, S., Craven, A., Klersy, C., Montecucco, C., Caporali, R., Watts, R., … on behalf of DCVAS Collaborators, including Chapman, P. T. (2021). Association between age at disease onset of anti-neutrophil cytoplasmic antibody–associated vasculitis and clinical presentation and short-term outcomes. Rheumatology, 60(2), 617-628. doi: 10.1093/rheumatology/keaa215

Stamp, L. K., & Chapman, P. T. (2020). Allopurinol hypersensitivity: Pathogenesis and prevention. Best Practice & Research: Clinical Rheumatology, 34, 101501. doi: 10.1016/j.berh.2020.101501

Stamp, L. K., Chapman, P. T., Barclay, M., Horne, A., Frampton, C., Merriman, T. R., Wright, D. F. B., … Dalbeth, N. (2020). Relationships between allopurinol dose, oxypurinol concentration and urate-lowering response: In search of a minimum effective oxypurinol concentration. Clinical & Translational Science, 13, 110-115. doi: 10.1111/cts.12686

Stamp, L. K., Chapman, P., Frampton, C., Duffull, S. B., Drake, J., Zhang, Y., & Neogi, T. (2020). Lack of effect of tart cherry concentrate dose on serum urate in people with gout. Rheumatology, 59, 2374-2380. doi: 10.1093/rheumatology/kez606

Becker, M., Graf, N., Sauter, R., Allanore, Y., Curram, J., Denton, C. P., … EUSTAR Collaborators, including Stebbings, S., Highton, J., Stamp, L., Chapman, P., & O'Donnell, J. (2019). Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: A European Scleroderma Trials and Research (EUSTAR) analysis. Annals of the Rheumatic Diseases, 78(9), 1242-1248. doi: 10.1136/annrheumdis-2019-215145

Sobanski, V., Giovannelli, J., Allanore, Y., Riemekasten, G., Airò, P., Vettori, S., … and the EUSTAR Collaborators, including Stebbings, S., Highton, J., Stamp, L., Chapman, P., & O'Donnell, J. (2019). Phenotypes determined by cluster analysis and their survival in the prospective European Scleroderma Trials and Research cohort of patients with systemic sclerosis. Arthritis & Rheumatology, 71(9), 1553-1570. doi: 10.1002/art.40906

Stamp, L. K., Chapman, P., Hudson, B., Frampton, C., Hamilton, G., & Judd, A. (2019). The challenges of managing gout in primary care: Results of a best-practice audit. Australian Journal of General Practice, 48(9), 631-637. doi: 10.31128/AJGP-04-19-4909

Stamp, L. K., O'Donnell, J. L., Frampton, C., Drake, J., Zhang, M., Barclay, M., & Chapman, P. (2019). A pilot randomized controlled double-blind trial of high- versus low-dose weekly folic acid in people with rheumatoid arthritis receiving methotrexate. Journal of Clinical Rheumatology, 25(7), 284-287. doi: 10.1097/RHU.0000000000000848

Wu, W., Jordan, S., Graf, N., de Oliveira Pena, J., Curram, J., Allanore, Y., … EUSTAR Collaborators, including Stebbings, S., Highton, J., Stamp, L., Chapman, P., & O'Donnell, J. (2019). Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort. Annals of the Rheumatic Diseases, 78(5), 648-656. doi: 10.1136/annrheumdis-2018-213455

Yeo, E., Palmer, S. C., Chapman, P. T., Frampton, C., & Stamp, L. K. (2019). Serum urate levels and therapy in adults treated with long-term dialysis: A retrospective cross-sectional study. Internal Medicine Journal, 49(7), 838-842. doi: 10.1111/imj.14163

Bursill, D., Taylor, W. J., Terkeltaub, R., Abhishek, A., So, A. K., Vargas-Santos, A. B., … Stamp, L., … Chapman, P. T., … Grainger, R., … Merriman, T., … Dalbeth, N. (2019). Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. Annals of the Rheumatic Diseases, 78(11), 1592-1600. doi: 10.1136/annrheumdis-2019-215933

Bursill, D., Taylor, W. J., Terkeltaub, R., Kuwabara, M., Merriman, T. R., Grainger, R., … Chapman, P. T., … Stamp, L. K., … Dalbeth, N. (2019). Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions for disease elements in gout. Arthritis Care & Research, 71(3), 427-434. doi: 10.1002/acr.23607

Stamp, L., Chapman, P., Barclay, M., Horne, A., Frampton, C., Merriman, T., Wright, D., … Dalbeth, N. (2019). Relationships between allopurinol dose, oxypurinol levels and serum urate: In search of an oxypurinol therapeutic concentration. Arthritis & Rheumatology, 71(Suppl. 10), 1222. doi: 10.1002/art.41108

Stamp, L., Zhang, Y., Frampton, C., Drake, J., Chapman, P., Duffull, S., & Neogi, T. (2019). Lack of effect of tart cherry concentrate dose on serum urate in people with gout. Arthritis & Rheumatology, 71(Suppl. 10), 0899. doi: 10.1002/art.41108

Stamp, L. K., Chapman, P. T., Barclay, M. L., Horne, A., Frampton, C., Tan, P., … Dalbeth, N. (2018). How much allopurinol does it take to get to target urate? Comparison of actual dose with creatinine clearance-based dose. Arthritis Research & Therapy, 20, 255. doi: 10.1186/s13075-018-1755-0

Stamp, L. K., Chapman, P. T., Barclay, M., Horne, A., Frampton, C., Tan, P., … Dalbeth, N. (2018). Can we predict inadequate response to allopurinol dose escalation? Analysis of a randomised controlled trial. Rheumatology, 57(12), 2183-2189. doi: 10.1093/rheumatology/key237

Stamp, L. K., Chapman, P. T., Barclay, M., Horne, A., Frampton, C., Tan, P., … Dalbeth, N. (2018). Can we predict inadequate response to allopurinol dose escalation? Analysis of a randomized controlled trial. Arthritis & Rheumatology, 70(9, Suppl.), 2229. doi: 10.1002/art.40700

Stamp, L. K., Chapman, P. T., Hudson, B., Hamilton, G., & Judd, A. (2018). The challenges of managing gout in primary care: Results of a best practice audit. Arthritis & Rheumatology, 70(9, Suppl.), 1265. doi: 10.1002/art.40700

Stamp, L., Chapman, P., Barclay, M., Horne, A., Tan, P., Drake, J., & Dalbeth, N. (2018). Can we predict inadequate response to allopurinol dose escalation? Analysis of a randomized controlled trial. Scandinavian Journal of Rheumatology, 47(Suppl. 129), (pp. 40-41). doi: 10.1080/03009742.2018.1487639

Stamp, L., Chapman, P., Hudson, B., Hamilton, G., & Judd, A. (2018). The challenges of managing gout in primary care: Results of a best practice audit. Scandinavian Journal of Rheumatology, 47(Suppl. 129), (pp. 6). doi: 10.1080/03009742.2018.1487639

Yeo, E., Palmer, S., Chapman, P. T., Frampton, C., & Stamp, L. K. (2018). Serum urate levels in people with gout on dialysis: Are we achieving treatment targets? Arthritis & Rheumatology, 70(9, Suppl.), 2230. doi: 10.1002/art.40700

Farquhar, H. J., McGettigan, B., Chapman, P. T., O'Donnell, J. L., Frampton, C., & Stamp, L. K. (2017). Incidence of anti-neutrophil cytoplasmic antibody-associated vasculitis before and after the February 2011 Christchurch Earthquake. Internal Medicine Journal, 47(1), 57-61. doi: 10.1111/imj.13246

McQueen, F. M., Chapman, P., Pollock, T., D’Souza, D., Lee, A. C., Dalbeth, N., Stamp, L., … Doyle, A. (2017). Changes in clinical disease activity are weakly linked to changes in MRI inflammation on treat-to-target escalation of therapy in rheumatoid arthritis. Arthritis Research & Therapy, 19, 241. doi: 10.1186/s13075-017-1433-7

Stamp, L. K., Chapman, P. T., Barclay, M. L., Horne, A., Frampton, C., Tan, P., … Dalbeth, N. (2017). A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Annals of the Rheumatic Diseases, 76(9), 1522-1528. doi: 10.1136/annrheumdis-2016-210872

Stamp, L. K., Chapman, P. T., Barclay, M., Horne, A., Frampton, C., Tan, P., … Dalbeth, N. (2017). Allopurinol dose escalation to achieve serum urate below 6 mg/dL: An open-label extension study. Annals of the Rheumatic Diseases, 76(12), 2065-2070. doi: 10.1136/annrheumdis-2017-211873

Stamp, L. K., Chapman, P. T., Barclay, M., Horne, A., Frampton, C., Tan, P., … Dalbeth, N. (2017). The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: A post hoc analysis of a randomized controlled trial. Arthritis Research & Therapy, 19(1), 283. doi: 10.1186/s13075-017-1491-x

Stamp, L. K., Haslett, J., Chapman, P., O'Donnell, J., Raja, R., Rothwell, A., Frampton, C., & Hooper, G. (2017). Rates of joint replacement surgery in New Zealand, 1999-2015: A comparison of rheumatoid arthritis and osteoarthritis. Journal of Rheumatology, 44(12), 1823-1827. doi: 10.3899/jrheum.170551

Wright, D. F. B., Doogue, M. P., Barclay, M. L., Chapman, P. T., Cross, N. B., Irvine, J. H., & Stamp, L. K. (2017). A population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis. European Journal of Clinical Pharmacology, 73, 71-78. doi: 10.1007/s00228-016-2133-y

Wright, S., Chapman, P. T., Frampton, C., O'Donnell, J. L., Raja, R., & Stamp, L. K. (2017). Management of gout in a hospital setting: A lost opportunity. Journal of Rheumatology, 44(10), 1493-1498. doi: 10.3899/jrheum.170387

Harun, S., Chambers, S., Hooper, G., Frampton, C., Chapman, P., Mohammed, R., … Haslett, J., Nolan, I., & Stamp, L. (2017). Prosthetic joint infections in Canterbury, New Zealand: A comparison of individuals with and without a rheumatic disease. Internal Medicine Journal, 47(Suppl. 2), (pp. 21). doi: 10.1111/imj.13426

McQueen, F. M., Chapman, P. T., Pollock, T., D'Souza, D., Lee, A., Dalbeth, N., Stamp, L. K., … Doyle, A. (2017). Changes in clinical disease activity are associated with changes in the total MRI inflammation score in rheumatoid arthritis patients who are escalating therapy in a treat-to-target (T2T) regimen. Arthritis & Rheumatology, 69(Suppl. 10), 1992. doi: 10.1002/art.40321

McQueen, F., Chapman, P., Pollock, T., D'Souza, D., Lee, A., Dalbeth, N., Stamp, L., … Doyle, A. (2017). Changes in the total MRI inflammation score as associated with changes in clinical disease activity in RA patients who are escalating therapy in a treat-to-target (T2T) regimen. Internal Medicine Journal, 47(Suppl. 2), (pp. 8-9). doi: 10.1111/imj.13426

Stamp, L. K., Chapman, P. T., Barclay, M., Horne, A., Frampton, C., Tan, P., … Dalbeth, N. (2017). Allopurinol dose escalation to achieve serum urate below 6mg/Dl: An open label extension study. Arthritis & Rheumatology, 69(Suppl. 10), 1105. doi: 10.1002/art.40321

Stamp, L. K., Chapman, P. T., & Palmer, S. C. (2016). Allopurinol and kidney function: An update. Joint Bone Spine, 83, 19-24. doi: 10.1016/j.jbspin.2015.03.013

de Lautour, H., Taylor, W. J., Adebajo, A., Alten, R., Burgos-Vargas, R., Chapman, P., … Stamp, L. K., … Dalbeth, N. (2016). Development of preliminary remission criteria for gout using Delphi and 1000Minds® consensus exercises. Arthritis Care & Research, 68(5), 667-672. doi: 10.1002/acr.22741

Wright, D. F. B., Doogue, M. P., Barclay, M. L., Chapman, P. T., Cross, N. B., Irvine, J. H., & Stamp, L. K. (2016). Predicting oxypurinol exposure in patients receiving intermittent haemodialysis. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Annual Scientific Meeting. (pp. 48). Retrieved from http://www.queenstownresearchweek.org/index.php/ascept-nz/

Johnston, M. E., Treharne, G. J., Chapman, P. T., & Stamp, L. K. (2015). Patient information about gout: An international review of existing educational resources. Journal of Rheumatology, 42(6), 975-978. doi: 10.3899/jrheum.141442

Stamp, L. K., Chapman, P. T., Francis, J., Beckert, L., Frampton, C., Watts, R. A., & O'Donnell, J. L. (2015). Association between environmental exposures and granulomatosis with polyangiitis in Canterbury, New Zealand. Arthritis Research & Therapy, 17, 333. doi: 10.1186/s13075-015-0852-6

Stamp, L. K., & Chapman, P. T. (2014). Urate-lowering therapy: Current options and future prospects for elderly patients with gout. Drugs & Aging, 31(11), 777-786. doi: 10.1007/s40266-014-0214-0

Sies, C. W., Florkowski, C. M., Frampton, C. M. A., O'Donnell, J. L., Chapman, P. T., & Stamp, L. K. (2014). Comparison of two plasma urate assays in patients receiving vitamin C supplementation [Chemical pathology]. Pathology, 46(4), 333-335. doi: 10.1097/pat.0000000000000095

Johnston, M., Treharne, G., Chapman, P. T., & Stamp, L. K. (2014). Self-management education for patients with gout: A review of existing resources. Arthritis & Rheumatology, 66(10, Suppl.), (pp. S72-S73). doi: 10.1002/art.38914

McGettigan, B., O'Donnell, J. L., Chapman, P. T., Frampton, C., & Stamp, L. K. (2014). An analysis of the incidence and characteristics of ANCA positive vasculitis before and after the Christchurch Earthquake. Arthritis & Rheumatology, 66(10, Suppl.), (pp. S771-S772). doi: 10.1002/art.38914

Stamp, L. K., Chapman, P. T., O'Donnell, J. L., Khalilova, I., Turner, R., & Kettle, A. (2014). Oxidative stress from use of allopurinol: Is there a reason for patients with gout to take vitamin C? Arthritis & Rheumatology, 66(10, Suppl.), (pp. S532-S533). doi: 10.1002/art.38914

Stamp, L. K., Chapman, P. T., Watts, R. A., Frampton, C., & O'Donnell, J. L. (2014). Environmental risk factors for granulomatous polyangiitis (GPA): Southern hemisphere similar to northern hemisphere. Arthritis & Rheumatology, 66(10, Suppl.), (pp. S772). doi: 10.1002/art.38914

Khan, E. A. R., Stamp, L. K., O'Donnell, J. L., & Chapman, P. T. (2013). Cardiovascular morbidity in rheumatoid arthritis patients in North Canterbury, New Zealand 1999–2008. International Journal of Rheumatic Diseases, 16(1), 19-23. doi: 10.1111/1756-185x.12008

Prowse, R. L., Dalbeth, N., Kavanaugh, A., Adebajo, A. O., Gaffo, A. L., Terkeltaub, R., … Stamp, L. K., … Chapman, P., … Grainger, R., … Taylor, W. J. (2013). A Delphi exercise to identify characteristic features of gout: Opinions from patients and physicians, the first stage in developing new classification criteria. Journal of Rheumatology, 40(4), 498-505. doi: 10.3899/jrheum.121037

Stamp, L. K., & Chapman, P. T. (2013). Gout and its comorbidities: Implications for therapy. Rheumatology, 52(1), 34-44. doi: 10.1093/rheumatology/kes211

Stamp, L. K., O'Donnell, J. L., Frampton, C., Drake, J. M., Zhang, M., & Chapman, P. T. (2013). Clinically insignificant effect of supplemental vitamin C on serum urate in patients with gout: A pilot randomized controlled trial. Arthritis & Rheumatism, 65(6), 1636-1642. doi: 10.1002/art.37925

Coman-Wright, N., Chapman, P. T., O'Donnell, J. L., & Stamp, L. K. (2013). Allopurinol dose above creatinine clearance based dose is safe and effective in gout: Compliance, efficacy and safety at 2 and 3 Years. Arthritis & Rheumatism, 65(10, Suppl.), (pp. S507). doi: 10.1002/art.38216

Raja, R., Chapman, P. T., O'Donnell, J. L., Ipenburg, J., Frampton, C., Hurst, M., & Stamp, L. K. (2012). Comparison of the 2010 American College of Rheumatology/European League Against Rheumatism and the 1987 American Rheumatism Association classification criteria for rheumatoid arthritis in an early arthritis cohort in New Zealand. Journal of Rheumatology, 39(11). doi: 10.3899/jrheum.120226

Stamp, L. K., & Chapman, P. T. (2012). Gout and organ transplantation. Current Rheumatology Reports, 14(2), 165-172. doi: 10.1007/s11926-012-0235-9

Stamp, L. K., Barclay, M. L., O'Donnell, J. L., Zhang, M., Drake, J., Frampton, C., & Chapman, P. T. (2012). Furosemide increases plasma oxypurinol without lowering serum urate—a complex drug interaction: Implications for clinical practice. Rheumatology, 51(9), 1670-1676. doi: 10.1093/rheumatology/kes091

Khan, A. R., Chapman, P. T., Stamp, L. K., Wells, J. E., & O'Donnell, J. L. (2012). Wegener's granulomatosis: Treatment and survival characteristics in a high-prevalence southern hemisphere region [Brief communication]. Internal Medicine Journal, 42(4), e23-e26. doi: 10.1111/j.1445-5994.2011.02700.x

Stamp, L. K., Ipenburg, J., Hurst, M., O'Donnell, J. L., Raja, R., Drake, J., & Chapman, P. T. (2012). The Christchurch earthquake: Providing a rheumatology service during a natural disaster [Brief report]. Clinical Rheumatology, 31(4), 723-725. doi: 10.1007/s10067-011-1913-0

Stamp, L. K., Frampton, C., O'Donnell, J. L., Drake, J., & Chapman, P. T. (2012). Lack of effect of supplemental vitamin C on serum urate in patients with gout. Arthritis & Rheumatism, 64(10, Suppl.), (pp. S60-S61). doi: 10.1002/art.37735

Stamp, L. K., & Chapman, P. (2011). Existing and emerging therapies for acute gout and long-term urate lowering. Current Rheumatology Reviews, 7(2), 141-151. doi: 10.2174/157339711795305031

Stamp, L. K., Barclay, M. L., O'Donnell, J. L., Zhang, M., Drake, J., Frampton, C., & Chapman, P. T. (2011). Relationship between serum urate and plasma oxypurinol in the management of gout: Determination of minimum plasma oxypurinol concentration to achieve a target serum urate level. Clinical Pharmacology & Therapeutics, 90(3), 392-398. doi: 10.1038/clpt.2011.113

Stamp, L. K., Barclay, M. L., O'Donnell, J. L., Zhang, M., Drake, J., Frampton, C., & Chapman, P. T. (2011). Effects of changing from oral to subcutaneous methotrexate on red blood cell methotrexate polyglutamate concentrations and disease activity in patients with rheumatoid arthritis. Journal of Rheumatology, 38(12), 2540-2547. doi: 10.3899/jrheum.110481

Stamp, L. K., O'Donnell, J. L., Zhang, M., James, J., Frampton, C., Barclay, M. L., & Chapman, P. T. (2011). Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including in those with renal impairment. Arthritis & Rheumatism, 63(2), 412-421. doi: 10.1002/art.30119

Raja, R., Chapman, P., O'Donnell, J., Ipenburg, J., & Stamp, L. (2011). Comparison of the 2010 ACR/EULAR and the 1987 ACR classification criteria for RA in an early arthritis cohort in New Zealand. Internal Medicine Journal, 41(Suppl. 1), (pp. 19). doi: 10.1111/j.1445-5994.2010.02466.x

Stamp, L. K., Chapman, P. T., Barclay, M., Kremer, J. M., & Dervieux, T. (2011). Red blood cell folate polyglutamates are an important determinant of RA disease activity in patients on Methotrexate: Implications for folic acid supplementation. Arthritis & Rheumatism, 63(Suppl. 10), (pp. S961-S962). doi: 10.1002/art.33310

Stamp, L. K., Chapman, P. T., O'Donnell, J. L., Zhang, M., James, J., Frampton, C., Barclay, M. L., Kennedy, M. A., & Roberts, R. L. (2010). Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate. Pharmacogenetics & Genomics, 20(6), 367-376. doi: 10.1097/FPC.0b013e3283398a71

Stamp, L. K., O'Donnell, J. L., Chapman, P. T., Zhang, M., James, J., Frampton, C., & Barclay, M. L. (2010). Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy. Arthritis & Rheumatism, 62(2), 359-368. doi: 10.1002/art.27201

White, D. H. N., Chapman, P. T., O'Donnell, J. L., James, J., Frampton, C., & Stamp, L. K. (2010). Lack of association between elevated mean red cell volume and haematological toxicity in patients receiving long-term methotrexate for rheumatoid arthritis. Internal Medicine Journal, 40(8), 561-565. doi: 10.1111/j.1445-5994.2009.02059.x

Stamp, L. K., O'Donnell, J. L., Barclay, M. L., Frampton, C., & Chapman, P. T. (2010). Response to comments [Letter to the editor]. Arthritis & Rheumatism, 62(8), 2560-2561. doi: 10.1002/art.27539

Barclay, M. L., Stamp, L. K., O'Donnell, J. L., Zhang, M., Drake, J., Frampton, C., & Chapman, P. T. (2010). Effects of changing from oral to subcutaneous administration of methotrexate on RBC MTX polyglutamate concentrations and disease activity in patients with rheumatoid arthritis. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Annual Scientific Meeting and the 6th Annual Carney Pharmacogenomics Symposium. ASCEPT. Retrieved from http://www.ascept.org.nz/

Stamp, L. K., O'Donnell, J. L., Chapman, P., Zhang, M., James, J., Frampton, C., & Barclay, M. (2010). The effect on MTX polyglutamate concentration profile after changing from oral to subcutaneous methotrexate in rheumatoid arthritis. Arthritis & Rheumatism, 62(Suppl. 10). doi: 10.1002/art.30166

Stamp, L. K., O'Donnell, J. L., Zhang, M., James, J., Frampton, C., Barclay, M. L., & Chapman, P. T. (2010). Using allopurinol above the dose based on creatinine clearance is effective and safe in chronic gout, including in those with renal impairment. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Annual Scientific Meeting and the 6th Annual Carney Pharmacogenomics Symposium. ASCEPT. Retrieved from http://www.ascept.org.nz/

Hollis-Moffatt, J. E., Merriman, M. E., Green, R. A., Rowley, K. A., Chapman, P. T., Dalbeth, N., … Harrison, A. A., Highton, J., … O'Donnell, J. L., Stamp, L. K., & Merriman, T. R. (2009). Evidence for association of an interleukin 23 receptor variant independent of the R381Q variant with rheumatoid arthritis. Annals of the Rheumatic Diseases, 68(8), 1340-1344. doi: 10.1136/ard.2008.090142

Stamp, L. K., O'Donnell, J. L., Chapman, P. T., Zhang, M., Frampton, C., James, J., & Barclay, M. L. (2009). Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment. Arthritis & Rheumatism, 60(8), 2248-2256. doi: 10.1002/art.24653

Stamp, L. K., O'Donnell, J. L., Chapman, P. T., Barclay, M. L., Kennedy, M. A., Frampton, C. M. A., & Roberts, R. L. (2009). Lack of association between HLA-G 14 bp insertion/deletion polymorphism and response to longterm therapy with methotrexate response in rheumatoid arthritis [Letter]. Annals of the Rheumatic Diseases, 68(1), 154-155. doi: 10.1136/ard.2008.089383

Barclay, M. L., Stamp, L. K., O'Donnell, J. L., Chapman, P. T., Zhang, M., Frampton, C., & James, J. (2009). Determinants of red blood cell methotrexate polyglutamate concentrations in patients with rheumatoid arthritis on long-term methotrexate. In D. Hay & S. Ngo (Eds.), Proceedings of the 43rd Annual Scientific Meeting of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists. 14. ASCEPT. [Abstract]

Dalrymple, J. M., Stamp, L. K., O'Donnell, J. L., Chapman, P. T., Zhang, M., & Barclay, M. L. (2008). Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis & Rheumatism, 58(11), 3299-3308.

McKinney, C., Merriman, M. E., Chapman, P. T., Gow, P. J., Harrison, A. A., Highton, J., … O'Donnell, J. L., … Stamp, L. K., Willis, J., … Merriman, T. R. (2008). Evidence for an influence of chemokine ligand 3-like 1 (CCL3L1) gene copy number on susceptibility to rheumatoid arthritis. Annals of the Rheumatic Diseases, 67, 409-413. doi: 10.1136/ard.2007.075028

Taylor, W. J., Harrison, A. A., Highton, J., Chapman, P., Stamp, L., Dockerty, J., … Sew Hoy, M. (2008). Disease Activity Score 28-ESR bears a similar relationship to treatment decisions across different rheumatologists, but misclassification is too frequent to replace physician judgement. Rheumatology, 47, 514-518. doi: 10.1093/rheumatology/ken004

Taylor, W. J., Schumacher, Jr, H. R., Baraf, H. S. B., Chapman, P., Stamp, L., Doherty, M., … Grainger, R., … Barskova, V. G. (2008). A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout. Annals of the Rheumatic Diseases, 67(6), 888-891. doi: 10.1136/ard.2007.079970

Jenks, K. A., Stamp, L. K., O'Donnell, J. L., Savage, R. L., & Chapman, P. T. (2007). Leflunomide-associated infections in rheumatoid arthritis. Journal of Rheumatology, 34, 2201-2203.

Meuli, K., Chapman, P., O'Donnell, J., Frampton, C., & Stamp, L. (2007). Audit of pneumocystis pneumonia in patients seen by the Christchurch Hospital rheumatology service over a 5-year period. Internal Medicine Journal, 37, 687-692.

O'Donnell, J. L., Hayman, M. W., Spellerberg, M. B., McLellan, A. D., Brooksbank, K., Chapman, P. T., & Stamp, L. K. (2007). Antineutrophil cytoplasmic antibody measurement: Advantages and disadvantages of a capture PR3 ELISA and a direct PR3 ELISA. Pathology, 39(2), 258-263.

O'Donnell, J. L., Stevanovic, V. R., Frampton, C., Stamp, L. K., & Chapman, P. T. (2007). Wegener's granulomatosis in New Zealand: Evidence for a latitude-dependent incidence gradient. Internal Medicine Journal, 37, 242-246.

Stamp, L. K., O'Donnell, J. L., & Chapman, P. T. (2007). Emerging therapies in the long-term management of hyperuricaemia and gout. Internal Medicine Journal, 37, 258-266.

Steer, S., Abkevich, V., Gutin, A., Cordell, H. J., Gendall, K. L., Merriman, M. E., Green, R. A., Rowley, K. A., Chapman, P., … Harrison, A. A., Highton, J., … O'Donnell, J., Stamp, L., … Merriman, T. R. (2007). Genomic DNA pooling for whole-genome association scans in complex disease: Empirical demonstration of efficacy in rheumatoid arthritis. Genes & Immunity, 8, 57-68. doi: 10.1038/sj.gene.6364359

Gibson, A., Stamp, L. K., Chapman, P. T., & O'Donnell, J. L. (2006). The epidemiology of Wegener's granulomatosis and microscopic polyangiitis in a Southern Hemisphere region. Rheumatology, 45, 624-628. doi: 10.1093/rheumatology/kei259

Savage, R. L., Highton, J., Boyd, I. W., & Chapman, P. (2006). Pneumonitis associated with leflunomide: A profile of New Zealand and Australian reports. Internal Medicine Journal, 36, 162-169.

Stamp, L., Ha, L., Searle, M., O'Donnell, J., Frampton, C., & Chapman, P. (2006). Gout in renal transplant recipients. Nephrology, 11(4), 367-371. doi: 10.1111/j.1440-1797.2006.00577.x

Stamp, L., Roberts, R., Kennedy, M., Barclay, M., O'Donnell, J., & Chapman, P. (2006). The use of low dose methotrexate in rheumatoid arthritis: Are we entering a new era of therapeutic drug monitoring and pharmacogenomics? Biomedicine & Pharmacotherapy, 60, 678-687.

Lynn, S. J., Sawyers, S. M., Moller, P. W., O'Donnell, J. L., & Chapman, P. T. (2005). Adult-onset inflammatory myopathy: North Canterbury experience 1989-2001. Internal Medicine Journal, 35, 170-173.

Simkins, H. M. A., Merriman, M. E., Highton, J., Chapman, P. T., O'Donnell, J. L., Jones, P. B. B., … Harrison, A. A., & Merriman, T. R. (2005). Association of the PTPN22 locus with rheumatoid arthritis in a New Zealand Caucasian cohort. Arthritis & Rheumatism, 52(7), 2222-2225.

Stamp, L., Searle, M., O'Donnell, J., & Chapman, P. (2005). Gout in solid organ transplantation: A challenging clinical problem. Drugs, 65(18), 2593-2611. doi: 10.2165/00003495-200565180-00004

Robinson, J. N., Sandom, J., & Chapman, P. T. (2004). Efficacy of pamidronate in complex regional pain syndrome type 1. Pain Medicine, 5(3), 276-280.

Solanki, K., Spellerberg, M., Chapman, P., Moller, P., & O'Donnell, J. (2004). Anti-cyclic citrullinated antibodies: Complementary to IgM rheumatoid factor in the early diagnosis of rheumatoid arthritis. New Zealand Medical Journal, 117(1203). Retrieved from http://journal.nzma.org.nz/journal/117-1203/1097/content.pdf

Burt, M. J., George, P. M., Upton, J. D., Collett, J. A., Chapman, P. T., Walmsley, T. A., Chapman, B. A., & Frampton, C. M. (1998). The frequency and effect on iron indices of haemochromatosis (HFE) gene mutations. Gut, 43, 830-836.

Chapman, P. T., Yarwood, H., Harrison, A., Stocker, C. J., Jamar, F., Gundel, R. H., … Haskard, D. O. (1997). Endothelial activation in monosodium urate monohydrate crystal-induced inflammation: in vitro and in vivo studies on the roles of tumor necrosis factor alpha and interleukin-1. Arthritis & Rheumatism, 40(5), 955-965.

Harrison, A. A., Stocker, C. J., Chapman, P. T., Tsang, Y. T., Huehns, T. T., Gundel, R. H., … Haskard, D. O. (1997). Expression of vascular cell adhesion molecule-1 by vascular endothelial cells in immune and nonimmune inflammatory reactions in the skin. Journal of Immunology, 159(9), 4546-4554.

Chapman, P. T., Jamar, F., Harrison, A., Schofield, J. B., Peters, A. M., Binns, R. M., & Haskard, D. O. (1996). Characterization of E-selectin expression, leucocyte traffic and clinical sequelae in urate crystal-induced inflamation: an insight into gout. British Journal of Rheumatology, 35, 323-334.

Davies, K. M., Chapman, P. T., Norsworthy, P. J., Jamar, F., Athanassiou, P., Keelan, E. T. M., Harrison, A., … Walport, P. J. (1995). Clearance pathways of soluble immune complexes in the pig: insights into the adaptive nature of antigen clearance in humans. Journal of Immunology, 155, 5760-5768.

Jamar, F., Chapman, P. T., Harrison, A., Binns, R. M., Haskard, D. O., & Peters, A. M. (1995). Inflamatory arthritis: imaging of endothelial cell activation with an indium-111-labeled F(ab')2 fragment of anti-E-selectin monoclonal. Radiology, 194, 843-850.

Are you looking for...

Are you looking for...

Are you looking for...

Are you looking for...

Are you looking for...

Are you looking for...

Are you looking for...

Publications